Leinco Technologies

Recombinant Human Fas Ligand (FasL)

Product Code:
 
LEI-F115
Product Group:
 
Recombinant Proteins
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-F115-10ug10 ug£329.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Format:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 with no calcium, magnesium, or preservatives.
Formulation:
This recombinant protein was 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 with no calcium, magnesium, or preservatives.
Long Description:
Fas ligand (FasL), also known as TNFSF6, is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family and is involved in membrane mediated apoptosis. The specific receptor for FasL is Fas (CD95, Apo-1). FasL is primarily expressed on activated T cells and NK cells, while Fas is expressed on various types of cells. Ligation of Fas by FasL triggers activation of the caspase cascade. Functional impairment of the Fas/FasL system is associated with the development and progression of malignancies. Tumor cells frequently exhibit de novo expression of FasL, which plays a significant role in local tissue destruction, metastatic spread and immune escape of the tumor cells.1 The apoptosis of lymphocytes, which occurs in autoimmune diseases, is usually induced by the Fas/FasLsystem, therefore, FasL is regarded as a potential target for immunotherapy.2 One study has suggested a correlation between high levels of FasL expression in the cornea and successful corneal transplantation.3
NCBI Gene:
356
Purity:
>95% by SDS-PAGE and analyzed by silver stain.
Target:
Fas Ligand

References

1. Igney, FH. et al. (2005) Cancer Immunol. Immunother. 54:11272. Ottmar, J. et al. (2008) Cell Communication and Signaling 6:113. Stuart, P. et al. (1997) J. Clin. Investigation 99:396